OSCR
Oscar Health, Inc.
OSCR has the edge over QDEL overall, supported by stronger fundamentals and lower modeled downside.
QDEL
QuidelOrtho Corporation
QDEL offers stronger modeled upside, but that advantage does not outweigh its weaker overall profile.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
QDEL Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Under pressure | |
| Weak |
QDEL's revenue and profitability are currently stable, but its cash flow and balance sheet are under pressure.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
QDEL PE Valuation
QDEL has no meaningful PE right now: it lost money over the past year.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
OSCR has the edge over QDEL on the outlook, with more favorable earnings and revenue expectations.
QDEL Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Decline | |
| Improving | |
| Limited | |
| High |
Analysts expect QDEL's profitability to improve, but its revenue to decline.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has the edge over QDEL on earnings quality, reporting a profit while its opponent remains loss making.
QDEL Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.90 | — |
| Q3 2026 | -$5.44 | +$11.84 |
| Q2 2026 | -$15.44 | -$8.64 |
| Q1 2026 | -$17.85 | -$12.62 |
| Q4 2025 | -$16.69 | +$13.85 |
| Q3 2025 | -$17.28 | +$10.61 |
| Q2 2025 | -$6.80 | +$20.98 |
| Q1 2025 | -$5.23 | +$21.15 |
| Q4 2024 | -$30.54 | -$30.39 |
QDEL is still losing money, but far less than before: $5.44 per share over the past year, against $30.54 at its worst in late 2024.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over QDEL on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR has the edge over QDEL on profitability, with a higher operating margin.
QDEL Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $618.9M | -12% |
| Q2 2026 | $630.9M | +2.8% |
| Q1 2026 | $619.8M | -11% |
| Q4 2025 | $723.6M | +2.2% |
| Q3 2025 | $699.9M | -3.7% |
| Q2 2025 | $613.9M | -3.6% |
| Q1 2025 | $692.8M | -2.6% |
| Q4 2024 | $707.8M | -4.7% |
QDEL's revenue has slid since its 2022 peak: $619M last quarter, down 12% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -1.2% | +100 points |
| Q2 2026 | -3.5% | +26 points |
| Q1 2026 | -5.1% | -9.8 points |
| Q4 2025 | -9.2% | +5 points |
| Q3 2025 | -101% | -103 points |
| Q2 2025 | -29% | -11 points |
| Q1 2025 | 4.7% | +252 points |
| Q4 2024 | -14% | -20 points |
QDEL's operating margin was −1.2% last quarter, up 99 points from the same quarter a year ago.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over QDEL on cash generation, producing positive trailing cash flow while its opponent burns cash.
QDEL Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.4M | +$93.3M |
| Q2 2026 | -$136.1M | -$51.8M |
| Q1 2026 | -$67M | -813% |
| Q4 2025 | $86.6M | +425% |
| Q3 2025 | -$94.7M | -233% |
| Q2 2025 | -$84.3M | +$48.9M |
| Q1 2025 | $9.4M | +$76.2M |
| Q4 2024 | $16.5M | -48% |
QDEL's free cash flow was −$118M over the past year, against −$153M the year before.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
QDEL Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.6% | +400K shares |
| 1 year | +1% | +700K shares |
| 3 years | +2.7% | +1.8M shares |
| 5 years | +62% | +26.2M shares |
| Available history | +59% | +25.4M shares |
QDEL has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2023 | $7.2M |
| Q4 2022 | — |
| Q3 2022 | $74.3M |
| Q1 2022 | — |
| Q4 2021 | — |
| Q3 2021 | $100,000 |
| Q2 2021 | $103.4M |
| Q1 2021 | — |
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has the edge over QDEL on leverage, with a lower net debt burden relative to earnings.
QDEL Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 8.3x | High |
| Q2 2025 | 11.9x | High |
| Q1 2025 | 8.6x | High |
| Q4 2023 | 3.9x | Elevated |
| Q3 2023 | 3.9x | Elevated |
| Q2 2023 | 3.8x | Elevated |
| Q1 2023 | 3.5x | Elevated |
| Q4 2022 | 2.3x | Moderate |
QDEL's net debt is about 8.3 years of its operating earnings (EBITDA), up from 3.9 years a year ago.
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
QDEL Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 39.3 | Neutral |
| Stochastic | 20.9 | Neutral |
QDEL's weekly RSI is 39 (neutral) and its Stochastic is 21 (neutral).
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
QDEL PE vs Healthcare Sector
| Metric | QDEL | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
QDEL has no meaningful PE right now: it lost money over the past year.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over QDEL on trend strength, trading above more of its moving averages.
QDEL Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $12.0 | 12% below |
| 20 week MA | $13.8 | 23% below |
| 50 week MA | $17.5 | 39% below |
| 100 week MA | $24.8 | 57% below |
| 200 week MA | $43.7 | 76% below |
QDEL is in a downtrend: it's below all five of its weekly moving averages, and 76% below its 200-week average.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over QDEL on returns for 2026, with the stronger performance.
QDEL Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $74.3 | $197.5 | +166% |
| 2021 | $197.5 | $137.4 | -30% |
| 2022 | $137.4 | $84.7 | -38% |
| 2023 | $84.7 | $73.7 | -13% |
| 2024 | $73.7 | $44.3 | -40% |
| 2025 | $44.3 | $29.3 | -34% |
| 2026 YTD | $29.3 | $10.6 | -64% |
QDEL has finished five years in a row lower, and it's down 64% so far in 2026.